A Phase 1b, Open-label, Multicenter Study of Urelumab (BMS-663513) in Combination With Rituximab in Subjects With Relapsed/Refractory B-cell Malignancies
Phase of Trial: Phase I
Latest Information Update: 22 Feb 2017
Price : $35 *
At a glance
- Drugs Urelumab (Primary) ; Rituximab
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 20 Sep 2016 Status changed from active, no longer recruiting to completed.
- 10 May 2016 Planned End Date changed from 1 Dec 2018 to 1 Aug 2016.
- 10 May 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Aug 2016.